Peptris Technologies, a Bengaluru-based artificial intelligence (AI) drug discovery company, has announced $1 million in pre seed round investment led by Speciale Invest. This strategic funding marks a pivotal step in boosting Peptris' efforts in advancing AI-driven solutions in the drug development/discovery sector, with a special focus on developing novel therapies for undruggable targets, particularly in oncology, inflammation, and rare diseases.

Peptris is revolutionising drug discovery through the implementation of its state-of-the-art AI platform. It is transforming the traditionally lengthy and costly drug discovery process, which often spans over a decade and incurs substantial costs, making essential medications financially out of reach for many.

This technology efficiently narrows down extensive chemical libraries to pinpoint promising drug candidates, marking a significant advancement over traditional drug discovery methods.

The company intends to leverage and capitalise on the recent maturation of AI technology in developing its proprietary drug discovery platform. The startup is broadening its research scope to include rare diseases, in addition to its ongoing work in oncology and inflammation.

The team has been incubated at Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru and has received grant support from various government agencies in the past, reinforcing the credibility and potential of its innovative approach.